Myricetin ameliorates the symptoms of collagen-induced arthritis in mice by inhibiting cathepsin K activity

References

• Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14:411–415
   PubMed Web of Science ®Google Scholar
• Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17
   PubMed Web of Science ®Google Scholar
• Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624–629
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Woodworth T, Henriksen K, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis – current and future applications, limitations and opportunities. Arthritis Res Ther 2011;13:215. doi: 10.1186/ar3280
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Pathogenesis of rheumatoid arthritis. Med Clin North Am 1977;81:29–55
   Web of Science ®Google Scholar
• Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233–255
   PubMed Web of Science ®Google Scholar
• Schett G. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 2008;41:224–229
   PubMed Web of Science ®Google Scholar
• Jones GC, Riley GP, Buttle DJ. The role of proteases in pathologies of the synovial joint. Int J Biochem Cell Biol 2008;40:1199–1218
   PubMed Web of Science ®Google Scholar
• Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009;18:585–600
   PubMed Web of Science ®Google Scholar
• Delaissé JM, Ledent P, Vaes G. Collagenolytic cysteine proteinases of bone tissue. Cathepsin B, (pro) cathepsin L and a cathepsin L-like 70kDa proteinase. J Biochem 1991;279:167–174
   Google Scholar
• Etherington DJ, Evans PJ. The action of cathepsin B and collagenolytic cathepsin in the degradation of collagen. Acta Biol Med Ger 1977;36:1555–1563
   PubMedGoogle Scholar
• Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. J Biochem 1998;331:727–732
   Google Scholar
• Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347–32352
   PubMed Web of Science ®Google Scholar
• Morko J, Kiviranta R, Joronen K, et al. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 2005;52:3713–3717
   PubMed Web of Science ®Google Scholar
• Skoumal M, Haberhauer G, Kolarz G, Hawa G, et al. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 2005;7:65–70
   PubMed Web of Science ®Google Scholar
• Weidauer E, Yasuda Y, Biswal BK, et al. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol Chem 2007;388:331–336
   PubMed Web of Science ®Google Scholar
• Chen KS, Xu C, Zhang JB. Red bayberry: botany and horticulture. Hortic Rev 2004;30:83–114
   Google Scholar
• Nonaka GI, Muta M, Nishioka I. Myricatin, a galloyl flavanonol sulfate and prodelphinidin gallates from Myrica rubra. Phytochemistry 1983;22:237–241
   Web of Science ®Google Scholar
• Sakurai N, Yaguchi Y, Inoue T. Triterpenoids from Myrica rubra. Phytochemistry 1986;26:217–219
   Web of Science ®Google Scholar
• Sakurai N, Yaguchi Y, Hirakawa T, et al. Two myricanol glycosides from Myrica rubra and revision of the structure of isomyricanone. Phytochemistry 1991;30:3077–3079
   Web of Science ®Google Scholar
• Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–1011
   PubMed Web of Science ®Google Scholar
• Ong KC, Khoo HE. Biological effects of myricetin. Gen Pharmacol 1997;29:121–126
   PubMedGoogle Scholar
• Tong Y, Zhou XM, Wang SJ, et al. Analgesic activity of myricetin isolated from Myrica rubra Sieb. Et Zucc. leaves. Arch Pharm Res 2009;2:527–533
   Web of Science ®Google Scholar
• Mukhtar H, Das M, Khan WA, et al. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a)anthracene-,benzo(a)pyrene-,3-methylcholanthrene-,andN-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res 1988;48:2361–2365
   PubMed Web of Science ®Google Scholar
• Lee KW, Kang NJ, Rogozin EA, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 2007;28:1918–1927
   PubMed Web of Science ®Google Scholar
• Kim JE, Kwon JY, Lee DE, et al. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 2009;77:412–421
   PubMed Web of Science ®Google Scholar
• Ono K, Nakane H, Fukushima M, et al. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem 1990;190:469–476
   PubMedGoogle Scholar
• de Whalley CV, Rankin SM, Hoult JR, et al. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem Pharmacol 1990;39:1743–1750
   PubMed Web of Science ®Google Scholar
• Wu C, Wang W, Tian B, et al. Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro. Biochem Pharmacol 2015;93:59–71
   PubMed Web of Science ®Google Scholar
• Ko SY. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells. Arch Oral Biol 2012;57:1623–1632
   PubMed Web of Science ®Google Scholar
• Larsson E, Erlandsson Harris H, Larsson A, et al. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 2004;43:428–434
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–975
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861–1874
   PubMed Web of Science ®Google Scholar
• Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659–672
   PubMed Web of Science ®Google Scholar
• Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007;8:315–323
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KW, Kim HY, et al. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 2010;79:1455–1461
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Fujii M, Hou DX. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem 2009;332:33–41
   PubMed Web of Science ®Google Scholar
• Yang SF, Wu Q, Sun AS, et al. Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin 2001;22:1089–1093
   PubMed Web of Science ®Google Scholar
• Willoughby S, Holmes A, Losalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002;1:273–288
   PubMedGoogle Scholar
• Hou WS, Li Z, Gordon RE, et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001;159:2167–2177
   PubMed Web of Science ®Google Scholar
• Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161:1419–1427
   PubMed Web of Science ®Google Scholar
• Schurigt U, Hummel KM, Petrow PK, et al. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor transgenic mice. Arthritis Rheum 2008;58:422–434
   PubMed Web of Science ®Google Scholar